Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine CandidatesPRNewsWire • 12/30/22
Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common StockPRNewsWire • 12/28/22
2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the PlagueThe Motley Fool • 12/16/22
Novavax stock sinks after proposed $125 million share sale, convertible debt offeringMarket Watch • 12/14/22
Is Novavax Stock A Buy On A Vaccines Rally Following Bullish Moderna News?Investors Business Daily • 12/13/22